AnaptysBio Inc. (NASDAQ:ANAB) shares are up on Monday as the company celebrates a favorable ruling from the Delaware Chancery Court regarding its Collaboration Agreement with Tesaro.
The court on Friday dismissed Tesaro’s anticipatory breach claim, which has contributed to a 12.64% increase in share price.
GSK Plc (NYSE:GSK) acquired Tesaro in December 2018 for approximately $5.1 billion (4.0 billion British pounds).
AnaptysBio Wins Delaware Court Ruling In Tesaro Dispute
The court’s decision confirms that Tesaro’s claim was insufficiently pleaded and rejects any requests for royalty reductions.
The ruling is seen as a validation of AnaptysBio’s efforts to protect its contractual rights related to the Jemperli royalty stream, with a trial scheduled for July 2026.
ANAB Technical Outlook: Momentum Near 52-Week Highs
AnaptysBio is currently trading near the upper end of its 52-week range, which suggests a bullish sentiment among investors.
The stock is trading 9.5% above its 50-day simple moving average (SMA), indicating strong short-term momentum, while it is 22.7% above its 100-day SMA, reflecting a positive intermediate trend.
The relative strength index (RSI) is at 47.84, suggesting that the stock is in neutral territory, with no immediate overbought or oversold conditions.
This positioning indicates that there is potential for further upward movement if buying pressure increases.
- Key Resistance: $67.00 — A critical level where upward momentum may stall.
- Key Support: $54.00 — A level that could provide buying interest if tested.
Over the past 30 days, the Healthcare sector has seen minimal movement, with a slight gain of 0.03%, while the 90-day performance shows a decline of 7.45%.
AnaptysBio’s rise today indicates it is leading sector gains, suggesting positive sentiment around its recent legal victory.
Analyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $75.00. Recent analyst moves include:
- Barclays: Overweight (Lowers Target to $63.00) (April 22)
- UBS: Buy (Lowers Target to $60.00) (April 21)
- Piper Sandler: Overweight (Raises Target to $95.00) (March 31)
ANAB Stock Price Activity: AnaptysBio shares were up 12.64% at $66.32 at the time of publication on Monday, according to Benzinga Pro data.
Image via Shutterstock
Recent Comments